Page 2 - Echogo Core News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Share this article Share this article OXFORD, England, Jan. 6, 2021 /PRNewswire/ -- A world-first, AI powered, outcomes-driven, decision support tool – EchoGo Pro, has been cleared by the FDA and is now available to clinicians across the U.S. EchoGo Pro was trialed and validated in the UK and US, improving the diagnostic accuracy of clinicians for Coronary Artery Disease (CAD), the most common form of heart disease and leading cause of death in the U.S. Ultromics’ EchoGo Pro uses AI to identify a higher possibility of coronary artery disease in an echo exam and sends a report to the clin...

FDA Clears Ultromics Echocardiography AI for Auto Identification of Coronary Artery Disease First-of-kind artificial intelligence solution in cardiac ultrasound will help clinicians diagnose disease Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical s...